rulesmate.com.au — Compliance reference
https://rulesmate.com.au/insights/therapeutic-goods-act-sponsor-obligations
Printed 6 November 2026
TGA Sponsor Obligations: ARTG Inclusion and Adverse Event Reporting
Plain-English guide to sponsor obligations under the Therapeutic Goods Act 1989: ARTG inclusion, conditions, pharmacovigilance and the 15-calendar-day reporting timeframe for serious adverse reactions to medicines.
Who counts as a sponsor and what they must do
Under the Therapeutic Goods Act 1989, a sponsor, in relation to therapeutic goods, is a person who exports or arranges the exportation of the goods from Australia, imports or arranges the importation of the goods into Australia, or, in Australia, manufactures the goods or arranges for another person to manufacture them for supply. A person who does those things on behalf of another person who is a resident of, or carries on business in, Australia is not the sponsor.
Therapeutic goods that are not exempt must generally be included in the Australian Register of Therapeutic Goods (ARTG) before they can be imported, exported, manufactured or supplied. The Act contains criminal offences (section 19B) and civil penalties (section 19D) relating to the registration or listing of goods that are imported, exported, manufactured and supplied. Registration or listing is subject to conditions determined by the Minister (section 28), which relate to matters such as manufacture, supply, record keeping and applicable standards.
The Therapeutic Goods Administration (TGA) regulates sponsors across the product lifecycle. Therapeutic Goods Advertising Code provides guidance on advertising therapeutic goods.
ARTG inclusion pathways
Therapeutic goods are included in the ARTG as either registered goods or listed goods. Medicines are either registered, which is the pathway for higher-risk medicines, or listed, which applies to lower-risk medicines. Medical devices and biologicals are included under separate frameworks set out in the Act and the regulations, with medical devices classified by risk.
An application for registration involves a sponsor's application and evidence to the TGA. The Act includes offences and a civil penalty for false statements in applications for registration (sections 22A and 22B).
Pharmacovigilance and adverse event reporting
The TGA's guidance for medicine sponsors states that sponsors of medicines approved for supply in Australia are legally responsible for meeting pharmacovigilance reporting requirements. Sponsors must let the TGA know who their Australian pharmacovigilance contact person is, submit serious adverse reaction reports, notify the TGA of safety issues they identify, and keep records relating to the reporting requirements.
According to the TGA's guidance, serious adverse reactions that occurred in Australia must be reported no later than 15 calendar days from the sponsor's awareness, counted from the day the four minimum data elements are received. Reports can be made as a CIOMS form by email, through the Adverse Event Management System (AEMS) in TGA Business Services, or by E2B reporting. The Australian pharmacovigilance contact person (A-PVCP) must be notified to the TGA within 15 calendar days of the sponsor's first medicine being entered on the ARTG, and updated details within 15 calendar days of any change.
Significant safety issues must be notified within 72 hours of the Australian sponsor's awareness, and other safety issues within 30 calendar days. Medical device sponsors are subject to separate adverse event reporting requirements.
Post-market monitoring and enforcement
Sponsors retain obligations after inclusion. A sponsor of a medicine must also include adverse reactions that are not routinely reported in a periodic safety update report (PSUR) where one is required, or supply them to the TGA on request.
The Secretary may suspend (section 29D) or cancel (section 30) the registration or listing of goods in the circumstances set out in the Act, including where failure to cancel would create an imminent risk of death, serious illness or serious injury. The Act also contains a criminal offence for failing to notify adverse effects (section 29A). Matters of professional conduct are separate and are covered by AHPRA Health Practitioner Regulation National Law.
Frequently asked
How quickly must sponsors report a serious adverse reaction?
For a medicine, the TGA's guidance requires serious adverse reactions that occurred in Australia to be reported as soon as possible and no later than 15 calendar days from the Australian sponsor's awareness (Day 0 is when the four minimum data elements are received).
Does a sponsor need to keep reporting if a product is no longer sold?
The Act's conditions of registration or listing (section 28) apply while the goods remain on the ARTG, and the TGA's pharmacovigilance guidance applies to sponsors of medicines approved for supply in Australia. The guidance reviewed does not provide an exemption for products that are no longer being sold.
Related
© Rules Mate · Source citations at the end · Information current as at 29 October 2026
Printed from https://rulesmate.com.au/insights/therapeutic-goods-act-sponsor-obligations